| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 43 | 2021 | 7783 | 1.370 |
Why?
|
| Ovarian Neoplasms | 21 | 2021 | 4795 | 1.160 |
Why?
|
| Positron-Emission Tomography | 15 | 2020 | 2197 | 1.100 |
Why?
|
| Uterine Cervical Neoplasms | 19 | 2022 | 1903 | 1.050 |
Why?
|
| Fluorodeoxyglucose F18 | 10 | 2020 | 1260 | 1.020 |
Why?
|
| Colonography, Computed Tomographic | 8 | 2014 | 55 | 0.900 |
Why?
|
| Cervix Uteri | 4 | 2016 | 247 | 0.850 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2020 | 7895 | 0.850 |
Why?
|
| Peritoneal Neoplasms | 9 | 2020 | 859 | 0.820 |
Why?
|
| Genital Neoplasms, Female | 6 | 2020 | 794 | 0.790 |
Why?
|
| Endometrial Neoplasms | 9 | 2020 | 1385 | 0.750 |
Why?
|
| Subtraction Technique | 3 | 2010 | 143 | 0.720 |
Why?
|
| CA-125 Antigen | 4 | 2020 | 229 | 0.610 |
Why?
|
| Diagnostic Imaging | 4 | 2010 | 1174 | 0.570 |
Why?
|
| Radiation Injuries | 8 | 2011 | 1471 | 0.560 |
Why?
|
| Hernia, Diaphragmatic | 2 | 2013 | 124 | 0.530 |
Why?
|
| Radiotherapy | 7 | 2011 | 1857 | 0.520 |
Why?
|
| Abdominal Neoplasms | 3 | 2006 | 251 | 0.480 |
Why?
|
| Colorectal Neoplasms | 8 | 2012 | 3707 | 0.470 |
Why?
|
| Rectal Neoplasms | 4 | 2011 | 1240 | 0.460 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2009 | 527 | 0.450 |
Why?
|
| Endometrium | 3 | 2016 | 457 | 0.430 |
Why?
|
| Thoracic Neoplasms | 2 | 2006 | 363 | 0.430 |
Why?
|
| Calcinosis | 1 | 2016 | 426 | 0.430 |
Why?
|
| Esophageal Neoplasms | 5 | 2013 | 3240 | 0.420 |
Why?
|
| Sensitivity and Specificity | 21 | 2017 | 5162 | 0.420 |
Why?
|
| Pelvic Neoplasms | 2 | 2006 | 199 | 0.420 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2014 | 155 | 0.410 |
Why?
|
| Neoplasm Staging | 26 | 2020 | 14012 | 0.390 |
Why?
|
| Esophagectomy | 2 | 2013 | 946 | 0.380 |
Why?
|
| Contrast Media | 9 | 2018 | 1499 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2020 | 10400 | 0.370 |
Why?
|
| Mullerian Ducts | 1 | 2011 | 79 | 0.370 |
Why?
|
| Female | 81 | 2022 | 148940 | 0.360 |
Why?
|
| Radiopharmaceuticals | 8 | 2013 | 1341 | 0.360 |
Why?
|
| Colonic Polyps | 6 | 2014 | 228 | 0.360 |
Why?
|
| Adenocarcinoma | 11 | 2013 | 7914 | 0.340 |
Why?
|
| Middle Aged | 58 | 2022 | 90352 | 0.340 |
Why?
|
| Tomography, Emission-Computed | 3 | 2007 | 334 | 0.340 |
Why?
|
| Aged | 49 | 2022 | 73333 | 0.330 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2020 | 880 | 0.330 |
Why?
|
| Humans | 97 | 2022 | 270740 | 0.310 |
Why?
|
| Adenoma | 5 | 2014 | 740 | 0.310 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 112 | 0.310 |
Why?
|
| Cystadenoma | 1 | 2007 | 28 | 0.300 |
Why?
|
| Adult | 45 | 2022 | 82040 | 0.270 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2020 | 499 | 0.270 |
Why?
|
| Radiographic Image Enhancement | 3 | 2018 | 410 | 0.260 |
Why?
|
| Pheochromocytoma | 1 | 2009 | 310 | 0.260 |
Why?
|
| BRCA2 Protein | 1 | 2007 | 380 | 0.250 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 4831 | 0.250 |
Why?
|
| Pelvic Bones | 2 | 2020 | 102 | 0.250 |
Why?
|
| Microsatellite Instability | 2 | 2018 | 408 | 0.250 |
Why?
|
| Aged, 80 and over | 22 | 2022 | 30998 | 0.240 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2006 | 625 | 0.220 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 339 | 0.220 |
Why?
|
| Tuberculosis | 1 | 2010 | 613 | 0.210 |
Why?
|
| Fractures, Bone | 2 | 2020 | 310 | 0.210 |
Why?
|
| Liver Diseases | 1 | 2007 | 602 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 1388 | 0.200 |
Why?
|
| Bone Density | 3 | 2022 | 466 | 0.200 |
Why?
|
| Pelvis | 2 | 2014 | 381 | 0.190 |
Why?
|
| Urogenital System | 1 | 2001 | 60 | 0.190 |
Why?
|
| Neoplasm, Residual | 4 | 2017 | 1754 | 0.190 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2021 | 38 | 0.190 |
Why?
|
| Image Enhancement | 3 | 2013 | 553 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 551 | 0.190 |
Why?
|
| Reproducibility of Results | 9 | 2017 | 6177 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 16689 | 0.180 |
Why?
|
| Urogenital Neoplasms | 1 | 2001 | 115 | 0.180 |
Why?
|
| Lymph Nodes | 4 | 2017 | 3077 | 0.180 |
Why?
|
| Radiography, Thoracic | 2 | 2010 | 477 | 0.180 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 128 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2013 | 15218 | 0.170 |
Why?
|
| Liver Neoplasms | 4 | 2011 | 4821 | 0.170 |
Why?
|
| Brachial Plexus | 2 | 1998 | 47 | 0.170 |
Why?
|
| Lymphatic Metastasis | 9 | 2013 | 4963 | 0.170 |
Why?
|
| Carcinoma | 3 | 2011 | 2610 | 0.170 |
Why?
|
| Esophageal Diseases | 1 | 2019 | 78 | 0.160 |
Why?
|
| Teratoma | 1 | 2021 | 248 | 0.160 |
Why?
|
| Radiotherapy, Conformal | 4 | 2013 | 898 | 0.160 |
Why?
|
| Lymphography | 3 | 2003 | 50 | 0.150 |
Why?
|
| Prospective Studies | 12 | 2022 | 13414 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5681 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2016 | 585 | 0.150 |
Why?
|
| Retrospective Studies | 16 | 2018 | 39890 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 10708 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 347 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 1999 | 190 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 4048 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 2 | 2011 | 427 | 0.140 |
Why?
|
| Gadolinium DTPA | 2 | 2018 | 173 | 0.140 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2017 | 57 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 496 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 107 | 0.130 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2002 | 296 | 0.130 |
Why?
|
| Predictive Value of Tests | 8 | 2018 | 4960 | 0.130 |
Why?
|
| Ultrasonography | 6 | 2021 | 1933 | 0.130 |
Why?
|
| Combined Modality Therapy | 7 | 2011 | 9039 | 0.130 |
Why?
|
| Colonic Neoplasms | 3 | 2014 | 1435 | 0.130 |
Why?
|
| Myometrium | 1 | 2015 | 82 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 495 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2017 | 517 | 0.120 |
Why?
|
| Brachytherapy | 4 | 2012 | 1005 | 0.120 |
Why?
|
| Male | 26 | 2014 | 128315 | 0.120 |
Why?
|
| Margins of Excision | 1 | 2016 | 315 | 0.110 |
Why?
|
| Observer Variation | 2 | 2013 | 709 | 0.110 |
Why?
|
| Intestine, Small | 3 | 2006 | 522 | 0.110 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 69 | 0.110 |
Why?
|
| Early Diagnosis | 2 | 2010 | 313 | 0.110 |
Why?
|
| Intestinal Neoplasms | 2 | 2006 | 205 | 0.110 |
Why?
|
| Lymphangioma, Cystic | 1 | 1993 | 23 | 0.110 |
Why?
|
| Research Design | 1 | 2010 | 1569 | 0.110 |
Why?
|
| Biopsy | 4 | 2019 | 3484 | 0.110 |
Why?
|
| Hysterectomy | 3 | 2013 | 654 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 2014 | 235 | 0.100 |
Why?
|
| Thymus Neoplasms | 1 | 1998 | 416 | 0.100 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 510 | 0.100 |
Why?
|
| Radiotherapy Dosage | 6 | 2007 | 4019 | 0.100 |
Why?
|
| Clinical Competence | 2 | 2011 | 1325 | 0.100 |
Why?
|
| Cisplatin | 3 | 2011 | 2497 | 0.100 |
Why?
|
| Fallopian Tube Diseases | 1 | 2012 | 19 | 0.100 |
Why?
|
| Colonoscopy | 5 | 2011 | 522 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2012 | 909 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2018 | 33737 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2016 | 1567 | 0.100 |
Why?
|
| Young Adult | 7 | 2022 | 22251 | 0.100 |
Why?
|
| Amifostine | 1 | 2011 | 99 | 0.090 |
Why?
|
| Smoking | 1 | 2010 | 2555 | 0.090 |
Why?
|
| Carcinoma, Adenosquamous | 3 | 2007 | 107 | 0.090 |
Why?
|
| Cathartics | 1 | 2011 | 40 | 0.090 |
Why?
|
| Electrolytes | 1 | 2011 | 63 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 129 | 0.090 |
Why?
|
| Citric Acid | 1 | 2011 | 53 | 0.090 |
Why?
|
| Phosphates | 1 | 2011 | 178 | 0.090 |
Why?
|
| Carboplatin | 2 | 2010 | 880 | 0.090 |
Why?
|
| Organometallic Compounds | 1 | 2011 | 209 | 0.090 |
Why?
|
| Incidence | 4 | 2013 | 5824 | 0.090 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2010 | 327 | 0.090 |
Why?
|
| Reference Values | 2 | 2010 | 1133 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2020 | 2178 | 0.080 |
Why?
|
| Viscera | 2 | 2006 | 92 | 0.080 |
Why?
|
| Uterine Diseases | 1 | 2009 | 38 | 0.080 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2009 | 20 | 0.080 |
Why?
|
| Colon | 2 | 2010 | 659 | 0.080 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 115 | 0.080 |
Why?
|
| Mifepristone | 1 | 2009 | 180 | 0.080 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 282 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 199 | 0.080 |
Why?
|
| Feasibility Studies | 6 | 2017 | 2353 | 0.080 |
Why?
|
| Prognosis | 8 | 2019 | 22505 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 9470 | 0.080 |
Why?
|
| Medical Illustration | 1 | 2007 | 31 | 0.080 |
Why?
|
| Mass Screening | 3 | 2012 | 1552 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 655 | 0.070 |
Why?
|
| Lymphoma | 2 | 2013 | 1519 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2013 | 5593 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 654 | 0.070 |
Why?
|
| Radiography | 4 | 2010 | 1986 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 596 | 0.070 |
Why?
|
| Sarcoma | 1 | 1998 | 1839 | 0.070 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 14617 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 841 | 0.070 |
Why?
|
| Research | 1 | 2009 | 427 | 0.070 |
Why?
|
| Survival Rate | 4 | 2018 | 12541 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2006 | 126 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 681 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2006 | 737 | 0.060 |
Why?
|
| Radiology | 1 | 2010 | 426 | 0.060 |
Why?
|
| Neoplasms | 2 | 2010 | 15927 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 622 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 901 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2013 | 3108 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 1347 | 0.060 |
Why?
|
| Mesentery | 1 | 2004 | 74 | 0.060 |
Why?
|
| Uterus | 1 | 2009 | 798 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 705 | 0.060 |
Why?
|
| Azacitidine | 1 | 2010 | 1218 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5315 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2004 | 110 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2006 | 605 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 639 | 0.050 |
Why?
|
| Taxoids | 2 | 2020 | 1015 | 0.050 |
Why?
|
| False Positive Reactions | 3 | 2010 | 375 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5408 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 5101 | 0.050 |
Why?
|
| Chemoradiotherapy | 3 | 2020 | 2027 | 0.050 |
Why?
|
| Minerals | 1 | 2022 | 72 | 0.050 |
Why?
|
| Urography | 1 | 2001 | 57 | 0.050 |
Why?
|
| Physical Examination | 2 | 2007 | 305 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 235 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 16215 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 1229 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2009 | 1465 | 0.040 |
Why?
|
| United States | 5 | 2014 | 15861 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2004 | 825 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 164 | 0.040 |
Why?
|
| Comorbidity | 1 | 2006 | 2394 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2010 | 179 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 190 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2003 | 647 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 236 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 15912 | 0.040 |
Why?
|
| Time Factors | 4 | 2013 | 13006 | 0.040 |
Why?
|
| Multimodal Imaging | 2 | 2013 | 550 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 1823 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2020 | 152 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 675 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 173 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 12033 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 186 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2020 | 232 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2020 | 704 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 32767 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2012 | 666 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2017 | 51 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 156 | 0.030 |
Why?
|
| Axilla | 2 | 1997 | 939 | 0.030 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2017 | 77 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2400 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2014 | 9292 | 0.030 |
Why?
|
| Omentum | 1 | 2017 | 108 | 0.030 |
Why?
|
| Ascites | 1 | 2017 | 213 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1042 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2008 | 6764 | 0.030 |
Why?
|
| Prevalence | 2 | 2014 | 3404 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2008 | 4000 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2000 | 502 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 5457 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2010 | 728 | 0.030 |
Why?
|
| Piperazines | 1 | 2004 | 2145 | 0.030 |
Why?
|
| Ribs | 1 | 1995 | 82 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 274 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 726 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 127 | 0.030 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 1604 | 0.030 |
Why?
|
| Lymph Node Excision | 3 | 2014 | 2062 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2012 | 10265 | 0.030 |
Why?
|
| Abdominal Wall | 1 | 2017 | 193 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 5923 | 0.030 |
Why?
|
| Neck | 1 | 1996 | 395 | 0.030 |
Why?
|
| Logistic Models | 2 | 2012 | 3444 | 0.030 |
Why?
|
| Movement | 2 | 2008 | 556 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 2331 | 0.030 |
Why?
|
| Rectum | 2 | 2005 | 480 | 0.030 |
Why?
|
| Diatrizoate | 1 | 2012 | 12 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 401 | 0.030 |
Why?
|
| Iohexol | 1 | 2012 | 56 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 2 | 2000 | 5257 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1253 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 2311 | 0.020 |
Why?
|
| Gastric Lavage | 1 | 2011 | 3 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 194 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2019 | 1207 | 0.020 |
Why?
|
| Mammography | 1 | 1997 | 1052 | 0.020 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 49 | 0.020 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2010 | 7 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2004 | 3669 | 0.020 |
Why?
|
| Bronchial Neoplasms | 1 | 2011 | 82 | 0.020 |
Why?
|
| Pubic Bone | 1 | 2010 | 16 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2828 | 0.020 |
Why?
|
| Acetabulum | 1 | 2010 | 41 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2010 | 120 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2020 | 2928 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 361 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4328 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2399 | 0.020 |
Why?
|
| Sacrum | 1 | 2010 | 138 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2010 | 176 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 88 | 0.020 |
Why?
|
| Aorta | 1 | 2013 | 670 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2010 | 282 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 984 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 382 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 347 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 425 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 397 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1999 | 2386 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 5231 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2006 | 37 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 325 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2011 | 513 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1642 | 0.020 |
Why?
|
| Risk Factors | 3 | 2010 | 17888 | 0.020 |
Why?
|
| Pancreas | 2 | 2000 | 744 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5776 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 518 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 1248 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 632 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 368 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4372 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1179 | 0.010 |
Why?
|
| Artifacts | 1 | 2007 | 536 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3530 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2170 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2008 | 1430 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2007 | 381 | 0.010 |
Why?
|
| Child | 2 | 1998 | 30559 | 0.010 |
Why?
|
| Software | 1 | 2011 | 1355 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 3028 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 453 | 0.010 |
Why?
|
| Iliac Artery | 1 | 2002 | 101 | 0.010 |
Why?
|
| Radiation Oncology | 1 | 2007 | 558 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2005 | 593 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2007 | 2033 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 3844 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 442 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 2315 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 727 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6867 | 0.010 |
Why?
|
| Recurrence | 1 | 2009 | 4878 | 0.010 |
Why?
|
| Intestines | 1 | 2005 | 736 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 2765 | 0.010 |
Why?
|
| Bile Ducts | 1 | 2000 | 115 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1691 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 3891 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 1999 | 41 | 0.010 |
Why?
|
| Transducers | 1 | 1998 | 56 | 0.010 |
Why?
|
| Spinal Nerve Roots | 1 | 1998 | 69 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 534 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1879 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 2232 | 0.010 |
Why?
|
| Dogs | 1 | 1999 | 1160 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 452 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 6449 | 0.010 |
Why?
|
| Feces | 1 | 1999 | 861 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 2457 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 4761 | 0.010 |
Why?
|
| Swine | 1 | 1999 | 1607 | 0.010 |
Why?
|
| Mastectomy | 1 | 1997 | 1553 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4958 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 3086 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1997 | 3145 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 17061 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 7381 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 61956 | 0.000 |
Why?
|